182 filings
Page 5 of 10
8-K
llgfy9il
5 May 21
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021
6:31am
8-K
ym9 yvf7r3vzt18ikbu
3 May 21
Entry into a Material Definitive Agreement
7:00am
8-K
7v86l6f9vt5foa w6
27 Apr 21
Departure of Directors or Certain Officers
7:05am
DEFA14A
oke1fc81ta4vk4ej0n
27 Apr 21
Additional proxy soliciting materials
6:49am
S-8
t8zutbcbjade
9 Mar 21
Registration of securities for employees
7:21am
8-K
xx1bmt ksj89j
9 Mar 21
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2020
7:07am
8-K
7j154nnqmerl2agakpc
9 Mar 21
Other Events
7:06am
8-K
r2m llnonvo83u12btl8
24 Feb 21
Surface Oncology to Participate in Upcoming March Investor Conferences
7:02am
8-K
y0e79ok904khcbhc
11 Feb 21
Surface Oncology to Appoint Robert Ross, M.D., as President and Chief Executive Officer
7:15am
8-K
rw2a3r6s6fgnet 7t8
11 Jan 21
Surface Oncology to Participate in H.C. Wainwright Bioconnect 2021 Conference
6:02am
8-K
dp14e qc9
17 Dec 20
Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program
7:05am
8-K
wvayg1w9xkh1dqu5j
25 Nov 20
Surface Oncology to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
7:00am
8-K
grsj350i
13 Nov 20
Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination and Expansion Stages of Ongoing Phase 1 Clinical Trials
7:00am
8-K
f3f0r575kn06u9q
12 Nov 20
Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer
6:58am
8-K
obtqy0movui cn
10 Nov 20
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2020
6:02am
8-K
xpivx 9ddhdr
9 Nov 20
Surface Oncology to Present at the Cowen IO Next Summit
4:01pm
8-K
a9vt4f3xsvkec5jvclo
9 Nov 20
Surface Oncology to Present SRF388 and SRF114 Preclinical Data at the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference
8:00am